Myriad Board Under Fire For Allegedly Overselling Gene Test

By Matthew Santoni (September 17, 2021, 7:57 PM EDT) -- A shareholder in Myriad Genetics Inc. told a Delaware federal court that company executives and directors lied to investors for years about a study of one of its flagship products, a genetic test intended to predict a patient's response to drugs for pain relief, ADHD and depression, according to the derivative suit filed Friday.

Karen Marcey said executives, including former CEO Mark Capone and Chief Financial Officer R. Bryan Riggsbee, had falsely claimed that a clinical trial supported using the GeneSight test to predict efficacy for all three categories of drugs, even after the U.S. Food and Drug Administration later explicitly...

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!